| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S87780-5mg促销 |
≥96% | ￥1620.00 ￥1450.00 |
10 | - | - | - | - |
|
S87780-10mg促销 |
≥96% | ￥3000.00 ￥2700.00 |
10 | - | - | - | - |
|
S87780-25mg促销 |
≥96% | ￥5260.00 ￥4730.00 |
5 | - | - | - | - |
|
S87780-50mg促销 |
≥96% | ￥7300.00 ￥6570.00 |
4 | - | - | - | - |
|
S87780-100mg促销 |
≥96% | ￥10000.00 ￥9000.00 |
1 | - | - | - | - |
|
| 产品描述： | B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | IC50: 50 nM (B7.1-CD28 interaction) | ||||||||||||||||||||
| 体外研究： | Bivalent CTLA4 homodimers bridge bivalent B7.1 homodimers to form an unusually stable signaling complex. Blocking B7/CD28 interactions with monoclonal antibodies or soluble receptors results in immunosuppression and enhanced allograft survival, while B7/CTLA-4 blockade results in enhanced antitumor immune responses. The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases. | ||||||||||||||||||||
| 参考文献： | 1. Green NJ, et al. Structure-activity studies of a series of dipyrazolo[3,4-b:3',4'-d]pyridin-3-ones binding to the immune regulatory protein B7.1. Bioorg Med Chem. 2003 Jul 3;11(13):2991-3013. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京